Shanghai Desano was initially established in 2000. Headquartered in Shanghai Zhangjiang Hi-tech park, Desano is dedicated to R&D, manufacturing, sales and marketing of high quality pharmaceutical drugs, focusing on the therapeutic area of global public health diseases such as HIV and malarial.

Located in Shanghai, Desano R&D center is National High-Tech Research & Development Center, National R&D and Engineering center of Anti-HIV Drugs and National Post-doctoral research station. With well-equipped facilities and high level R&D staff, Desano R&D center provides strong capability of research and innovation including process R&D and optimization, as well as analytical method development. Owning two National High-tech companies, Desano has established four manufacturing sites of formulation, API and intermediate with cGMP and EHS standards in Shanghai and Jiangsu Province.

Desano is one of the first companies launching generic ARVs in China since 2002. Multiple products of Desano passed GMP inspection of US FDA, UK MHRA, EU EMA, EDQM, Australia TGA and WHO of various anti-HIV drugs. Commercial manufacturing facilities were established to meet the increasing demand of global treatment of HIV and malarial patients. Desano is one of the key APIs suppliers to ARVs finished product manufacturers. Every year Desano supports the treatment of over 6 million ARVs finished products.